GlassScriptPhysician profile
Bachir Berbari
NPI 1407288996
$5,521.66
in general payments reported to CMS, 2019-2025
45 companies · $1,684 in 2025
The $1,684 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,134 · 2020: $110 · 2021: $249 · 2022: $1,019 · 2023: $554 · 2024: $771 · 2025: $1,684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,809 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,808.79 |
| Education | $199.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,097.43 | 2021-2025 | Erleada, Darzalex, Tecvayli |
| Pfizer INC. | $420.88 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $410.00 | 2019-2025 | Enhertu, Tagrisso |
| Novartis Pharmaceuticals Corporation | $401.17 | 2019-2025 | |
| Abbvie INC. | $295.01 | 2022-2025 | Venclexta |
| Genzyme Corporation | $276.90 | 2022-2025 | |
| Incyte Corporation | $272.69 | 2019-2025 | Jakafi, Zynyz |
| Merck Sharp & Dohme LLC | $203.56 | 2019-2025 | Keytruda, Lynparza |
| Astellas Pharma US INC | $187.03 | 2019-2025 | Vyloy |
| Genentech USA, INC. | $183.91 | 2019-2025 | Tecentriq, Itovebi, Venclexta |
| Amgen INC. | $170.06 | 2019-2022 | |
| Daiichi Sankyo INC. | $167.18 | 2022-2025 | Enhertu, Injectafer, Datroway |
| E.R. Squibb & Sons, L.L.C. | $144.74 | 2019-2025 | Reblozyl, Opdualag |
| Bayer Healthcare Pharmaceuticals INC. | $141.70 | 2019-2025 | |
| Adaptive Biotechnologies Corporation | $133.03 | 2022-2025 | Clonoseq |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bachir Berbari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.